Figures computed from official regulatory filings — .
Analysttarget 8.25 USD (+1989%)
Ownershipinsiders 4.72% · institutions 4.65% · short 6.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Ensysce Biosciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
9 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| GOWER BOB Gtrack record | Buy | $198K | conv 43 |
| GOWER BOB Gtrack record | Buy | $246.2K | conv 70First in 12mo | SEC |
| GOWER BOB Gtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| GOWER BOB Gtrack record | Buy | $44.2K | conv 22 | SEC |
| GOWER BOB Gtrack record | Buy | $129.6K | conv 30 | SEC |
| GOWER BOB Gtrack record | Buy | $53.6K | conv 28 | SEC |
| GOWER BOB Gtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| GOWER BOB Gtrack record | Buy | $500K | conv 84Unusual sizeFirst in 12mo | SEC |
| Rosebraugh Curtis | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Benton Andrew | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Martin Steven Robert | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| GOWER BOB Gtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Rauch Lee M. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Levin Adam | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Chang William H | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Kirkpatrick Lynn | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Kirkpatrick Lynn | Buy | $14.3K | conv 47 | SEC |
| Kirkpatrick Lynn | Buy | $34.3K | conv 68First in 12mo | SEC |
| Kirkpatrick Lynn | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Humphrey David Carl | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Birkett Kevin Geoffrey | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Chang William H | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Rosebraugh Curtis | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Martin Steven Robert | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| GOWER BOB Gtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |